Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...and into the valley of death rode the six hundred
Synergy getting bought or licensing partner. form 14A, 150 million more shares being auth'd for purposes of share and warrant conversion prior to buyout. Proxy form says NOT being done to prevent hostile takeover
new article on Synergy:
http://seekingalpha.com/article/3045036-synergy-pharmaceuticals-dont-be-an-april-fool
....and it's not even difficult to look up this information:
http://finance.yahoo.com/q/mh?s=IRWD+Major+Holders
http://www.nasdaq.com/symbol/irwd/insider-trades
oh well...
Agree, quite a few people (like you & that poster) show their ignorance about share structure / numbers A vs B on public message boards
I can explain it for you, I can't understand it for you
So, this story that is all over the web, and easy to google, and print is all wrong? Wouldn't this guy be open to lawsuits for false reporting, slander? Oh well
Maybe you did get "scooped"
Maybe he just wants a new car?
What's this?
Insider Selling: Peter M. Hecht Sells 200,000 Shares of Ironwood Pharmaceuticals Stock (IRWD)
Posted by Scott Davis on Mar 19th, 2015 // No Comments
Share on StockTwits
Ironwood Pharmaceuticals logoIronwood Pharmaceuticals (NASDAQ:IRWD) CEO Peter M. Hecht sold 200,000 shares of Ironwood Pharmaceuticals stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $15.62, for a total transaction of $3,124,000.00. Following the completion of the sale, the chief executive officer now directly owns 73,418 shares in the company, valued at approximately $1,146,789.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 15.66 on Thursday. Ironwood Pharmaceuticals has a 52-week low of $9.01 and a 52-week high of $17.11. The stock has a 50-day moving average of $15. and a 200-day moving average of $14.. The company’s market cap is $2.21 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on
only fools post lies that are easy to disprove:
If you had checked yahoo finance or nadaq.com, you would know he executed options:
HECHT PETER M Officer: 03/17/2015 Sell direct 125,000 at $15.6100, 4,141,417 shares owned post transaction
HECHT PETER M Officer 03/17/2015 Option Execute direct 125,000 at $1.5600, 4,266,417 shares owned post transaction
option price executed was $1.56, so those are evidently pretty old, pre-IPO options that probably came up on their expiration date.
Read more: http://www.nasdaq.com/symbol/irwd/insider-trades#ixzz3V1lqeBBv
As for share ownership (s. above, >4 million shares): to put it in perspective, the CEO of IRWD owns more shares than 141 of the 150 institutional investors in IRWD, compare:
http://www.nasdaq.com/symbol/irwd/institutional-holdings
I would encourage you to look up the CEO salaries for the CEO of IRWD, a company with a (profitable) product on the market, and the CEO of SGYP, a company with no FDA approved product, in the relevant SEC filings.
that's the real eye opener, IMHO.
Good luck !
why oh why did IRWD supposedly get a takeover bid when they only own 50% of a drug ? why not SGYP when it is much cheaper and owns 100% of the "best in class" (tongue in cheek) - oh why indeed....
did he sell so he could buy SGYP on the sly? because there is more of an arbitrage? Why sell 200 k if the price is going up?
did Hecht, the ceo, just sell 200,00 of his 275,000 shares at market price? why
if you're not reading the SGYP & IRWD message boards on Yahoo Finance on a regular basis, this article may be easily overlooked:
http://www.dailymail.co.uk/money/markets/article-3002951/MARKET-REPORT-Biopharma-takeover-mania-continues-grip-world-stockmarkets.html
Link to the IRWD presentation at the JP Morgan Healthcare Conference earlier this week:
http://files.shareholder.com/downloads/ABEA-45DU4J/3482467949x0x802603/f02582f8-9e66-4d87-8ab7-c34e900c0bed/Ironwood_Overview_JPM2015.pdf
institutional ownership has been hovering at ~105-110% for months now, indicating ongoing share borrowing efforts for short covering. air's getting thinner for the large short position holders IMO
I've seen it on other securities but never here. Usually means nothing but we'll know in minutes.
strange ask ($146.70 shown on yahoo fin.) this morning after the open, haven't seen that before
Ironwood 3Q 2014 investor presentation link :
http://files.shareholder.com/downloads/ABEA-45DU4J/3482467949x0x791307/6AC22504-8946-4D74-99AF-EF31F889640C/IRWD.3Q14InvestorUpdate.slides.pdf
as a matter of fact, due to the PPS of IRWD / SGYP ~ 5/1, in Dollar terms, the short volume for IRWD is about five times that of SGYP.
and yet, here we are, with IRWD slowly creeping up towards the 52wk high....
what might that tell a discerning observer ?
http://www.nasdaq.com/symbol/sgyp/short-interest
http://www.nasdaq.com/symbol/irwd/short-interest
Nope. Short volume on SGYP and IRWD is in the same neighborhood (both around ~15 mill shares)
Happy & Blessed Christmas!
that Cowen analyst's gettin a big ole lump of coal for Christmas LOL
Synergy's web site under presentations, 10/20 or 10/21
No red ribbons for 2nd place
Impossible to refute SGYP's better numbers
and synergy's drug is not an ebola analog
Plecanatide has higher responder rate, which means more people will stick with it
SGYP amazing results, 1/2 the poops
Plecanaitde 9% diarrhea vs Linzess 20%. Plecanatide 42% responder rate vs Linzess 34
Sorry, SGYP is best in Class, and ahead in their OIC trials, and they don't need QT testing
SGYP amazing results, 1/2 the poops
Plecanaitde 9% diarrhea vs Linzess 20%. Plecanatide 42% responder rate vs Linzess 34
Cowen? same guys that recently upgraded Synergy (SGYP) & downgraded IRWD LOL ?
$IRWD Ironwood: IMS Data Points To A Likely Beat On Linzess Sales But Costs Remain A Concern, Says Cowen http://www.smarteranalyst.com/2014/10/10/ironwood-ims-data-points-likely-beat-linzess-sales-costs-remain-concern-says-cowen/
better return to the SGYP board. they need some hand holding there. just set yet another 52 wk low this morning ($ 2.62)...
Sep 10 investor call at Morgan Stanley Global Healthcare Conference :
http://investor.ironwoodpharma.com/eventdetail.cfm?EventID=149997
it's audio only. "what's next in the pipeline" is discussed in a little more detail for the first time.
The sGC platform is what intrigues me the most. Bayer just signed a huge ($1billion+) partnership with Merck in that field. hot area.
SGYP, that is
If I were so confident of irwd going to 8 I'd just short it and make more cash right?
why waste time on this board then?
off you go, hop back on your unicorn & back to the SGYP board...Dorothy needs company following the yellow brick road...
Cowen PT of 10, that's a drop from here
Cowen downgrades IRWD, upgrades SGYP
broke through both the 50 ($13.70) and 200 MDA ($13.47) today
how is that shorting strategy working out for you ?
still hoping for the $ 8 PPS here ?
hoping for $ 2 for SGYP as well ? at least that might have a higher chance of coming true LOL
Another UNSATISFIED customer says, not a med reaction I would want
Condition: Irritable Bowel Syndrome with Constipation
7/2/2014 5:04:03 PM
.
Reviewer: shncon, 35-44 Male on Treatment for 1 to 6 months (Patient)
Effectiveness
Current Rating: 3
.
Ease of Use
Current Rating: 3
.
Satisfaction
Current Rating: 3
.
Comment:
I was prescribed this for IBS with Constipation. My original complaint was constant bloating and constipation. I had a colonoscopy done and then I was diagnosed with IBS. Ive been taking the LInzess for 2 months and the bloating continues. I can pretty much time my BM of diarrhea about 1.5 - 2 hours after I take my pill. I then have liquid stools for the next few hours and then I go right back to constipation. Not sure what's going on?
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
260
|
Created
|
06/22/11
|
Type
|
Free
|
Moderators |
http://www.ironwoodpharma.com/
http://finance.yahoo.com/q/ks?s=IRWD+Key+Statistics
Ironwood Pharmaceuticals, Inc. discovers, develops, and commercializes medicines targeting therapeutic needs. The company is developing Linaclotide, a first-in-class compound that is in confirmatory Phase III clinical trials for the treatment of irritable bowel syndrome with constipation, chronic constipation, and other lower gastrointestinal conditions. It also focuses on one Phase I pain drug candidate and multiple preclinical programs, as well as on building a specialty biochemicals business based on a proprietary strain-development platform. The company has a collaboration agreement with Forest Laboratories, Inc. to jointly develop and commercialize linaclotide in North America; a license agreement with Almirall, S.A. to develop and commercialize linaclotide in Europe; a license agreement with Astellas Pharma Inc. that provides Astellas Pharma with the right to develop and commercialize linaclotide in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia. It was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Overview article on Linaclotide, the company's lead drug: http://en.wikipedia.org/wiki/Linaclotide
Updated IRWD short volume numbers (source: www.nasdaq.com)
Settlement Date Short Interest
11/28/2014 14,593,658
11/14/2014 14,892,420
10/31/2014 14,952,106
10/15/2014 16,259,737
9/30/2014 15,155,353
6/30/2014 13,498,802
3/31/2014 18,224,084
12/31/2013 22,378,583
Total outstanding shares: 120 million (as of 03/31/2014)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |